Most people with peritoneal cancer have other cancers that have spread. Doctors only diagnose the disease in the advanced stages, so the prognosis can be short in some individuals. However, survival ...

Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after ...

The study consisted of 62 eligible and assessable patients, median age 57 years, 41 (66.1%) having received two prior regimens and 36 (58.1%) considered platinum resistant. Grade 3 adverse events at ...

Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a type ...

Seven hundred sixty-two patients with stage IV or suboptimally debulked stage III ovarian or primary peritoneal cancer were randomly assigned to receive either valspodar 5 mg/kg every 6 hours for 12 ...

The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with ...

Vadodara: Doctors at a city-based hospital have successfully treated a rare and aggressive abdominal cancer in a 29-year-old ...

First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s raludotatug deruxtecan based on phase 1 trial and REJOICE-Ovarian01 phase 2/3 trial Second Breakthrough Therapy Designation since ...

A new wave of cancer treatments is looking promising for the future of oncologic care. The ovarian cancer drug RC88, which is made by the Chinese biopharmaceutical company RemeGen, received FDA ...